Technical Analysis for AMGN - Amgen Inc.
|Grade||Last Price||% Change||Price Change|
AMGN closed down 2.76 percent on Friday, December 14, 2018, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
|Weak or Absent||Up||Down||Down|
|See historical AMGN trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 14||Fell Below 20 DMA||Bearish||0.00%|
|Dec 14||Fell Below 50 DMA||Bearish||0.00%|
|Dec 14||MACD Bearish Centerline Cross||Bearish||0.00%|
|Dec 14||180 Bearish Setup||Bearish Swing Setup||0.00%|
|Dec 14||Cup with Handle||Other||0.00%|
|Dec 13||20 DMA Support||Bullish||-2.76%|
|Dec 13||Crossed Above 50 DMA||Bullish||-2.76%|
|Dec 13||Cup with Handle||Other||-2.76%|
|Dec 13||Narrow Range Bar||Range Contraction||-2.76%|
|Dec 13||NR7||Range Contraction||-2.76%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Its principal products include Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body fight infections; Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases; Aranesp and EPOGEN erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides product candidates in mid- to late-stage development in various therapeutic areas comprising oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine, which includes neuroscience. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; and UCB, as well as a strategic alliance with Astellas Pharma Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more AMGN news...
|52 Week High||210.19|
|52 Week Low||163.31|
|200-Day Moving Average||189.077|
|50-Day Moving Average||195.9896|
|20-Day Moving Average||196.709|
|10-Day Moving Average||197.567|
|Average True Range||5.2414|
|Chandelier Exit (Long, 3 ATRs )||193.2658|
|Chandelier Exit (Short, 3 ATRs )||202.8442|
|Upper Bollinger Band||205.149|
|Lower Bollinger Band||188.269|
|Percent B (%b)||0.23|
|MACD Signal Line||0.4944|
|Market Cap||140.15 Billion|
|Num Shares||730 Million|
|Price-to-Earnings (P/E) Ratio||17.49|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||198.81|
|Resistance 3 (R3)||199.42||197.78||197.68|
|Resistance 2 (R2)||197.78||196.07||197.48||197.31|
|Resistance 1 (R1)||194.93||195.01||194.11||194.32||196.93|
|Support 1 (S1)||190.44||191.58||189.62||189.83||187.21|
|Support 2 (S2)||188.80||190.52||188.50||186.83|
|Support 3 (S3)||185.95||188.80||186.46|
|Support 4 (S4)||185.34|